BNP Paribas set a €85.00 ($101.19) price objective on Sanofi SA (EPA:SAN) in a research report report published on Tuesday. The brokerage currently has a neutral rating on the stock.

Several other brokerages have also recently weighed in on SAN. J P Morgan Chase & Co set a €95.00 ($113.10) price target on Sanofi SA and gave the company a neutral rating in a research report on Thursday, June 22nd. Jefferies Group LLC set a €92.00 ($109.52) price objective on Sanofi SA and gave the company a neutral rating in a research note on Monday, May 29th. Credit Suisse Group set a €95.00 ($113.10) price objective on Sanofi SA and gave the company a buy rating in a research note on Tuesday, July 4th. Kepler Capital Markets set a €89.00 ($105.95) price target on Sanofi SA and gave the stock a buy rating in a research note on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) price target on Sanofi SA and gave the stock a neutral rating in a research note on Wednesday, May 24th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have issued a buy rating to the company. Sanofi SA currently has a consensus rating of Hold and a consensus price target of €87.88 ($104.61).

Sanofi SA (EPA:SAN) opened at 81.37 on Tuesday. Sanofi SA has a 12-month low of €24.55 and a 12-month high of €82.67. The company’s 50 day moving average price is €26.12 and its 200-day moving average price is €25.99. The firm has a market capitalization of €102.18 billion and a price-to-earnings ratio of 11.35.

TRADEMARK VIOLATION NOTICE: This report was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/sanofi-sa-san-given-a-85-00-price-target-at-bnp-paribas.html.

About Sanofi SA

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.